How GLP-1 medications support meaningful, sustainable weight loss. Learn what realistic results look like, what to expect over time, and how to maximize progress and maintain it for the long term.
Weight Loss
Many people regain weight after stopping GLP-1 medications like semaglutide or tirzepatide. A new Dartmouth Health study offers promising clues about what helps some patients keep the weight off. Here is what the research means for you and your treatment plan.
One of the biggest downsides of GLP-1 medications is that weight loss often includes muscle, not just fat. A new oral pill in development may help protect lean muscle mass during GLP-1 treatment, addressing one of the most common concerns patients and doctors share about these medications.
GLP-1 medications like semaglutide and tirzepatide have helped millions lose significant weight, but they come with real risks worth understanding. This guide breaks down what the science actually shows, what side effects to watch for, and what questions to ask your doctor before starting.
New clinical trial data from Novo Nordisk shows a higher dose of semaglutide (Wegovy) may produce nearly 28% body weight loss in early responders. Here is what that means for patients currently on GLP-1 therapy, those considering it, and how this could shape treatment decisions going forward.
Novo Nordisk has reported that a higher-dose formulation of Wegovy (semaglutide) achieved roughly 28% weight loss in early responders. This could reshape how doctors approach dosing for patients who respond well early in treatment. Here's what the data means for you and questions worth asking your provider.
Some budget-friendly supplements show modest weight loss benefits in early research, but how do they stack up against GLP-1 medications like semaglutide and tirzepatide? This article breaks down the science, the costs, and how to decide which approach fits your situation.
A new study reveals a troubling paradox: people who successfully lose weight using Ozempic are judged more harshly than people who don't lose weight at all. The findings highlight deep-seated biases about "earned" weight loss that GLP-1 patients face daily. Understanding this stigma can help you prepare, advocate for yourself, and stay focused on your health goals.
Bariatric surgeons across the country are watching GLP-1 medications change the weight loss landscape. This article breaks down how drugs like semaglutide and tirzepatide fit alongside surgical options, what the evidence says, and how to decide which path is right for you.
.avif)
